Cases in the management of metastatic colorectal cancer: Regorafenib as second-line therapy after FOLFOXIRI plus bevacizumab in a patient with a KRAS mutation

Tanios S. Bekaii-Saab

Cases in the management of metastatic colorectal cancer: Regorafenib as second-line therapy after FOLFOXIRI plus bevacizumab in a patient with a KRAS mutation

Hematology/Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Journal	Clinical Advances in Hematology and Oncology
Volume	19
Issue number	8
State	Published - Oct 2021

ASJC Scopus subject areas

Hematology
Oncology

Cite this

@article{a536939ec3094f0a87ffad9b9843cf5b,

title = "Cases in the management of metastatic colorectal cancer: Regorafenib as second-line therapy after FOLFOXIRI plus bevacizumab in a patient with a KRAS mutation",

author = "Bekaii-Saab, {Tanios S.}",

year = "2021",

month = oct,

language = "English (US)",

volume = "19",

journal = "Clinical Advances in Hematology and Oncology",

issn = "1543-0790",

publisher = "Millennium Medical Publishing, Inc.",

number = "8",

}

TY - JOUR

T1 - Cases in the management of metastatic colorectal cancer

T2 - Regorafenib as second-line therapy after FOLFOXIRI plus bevacizumab in a patient with a KRAS mutation

AU - Bekaii-Saab, Tanios S.

PY - 2021/10

Y1 - 2021/10

UR - http://www.scopus.com/inward/record.url?scp=85117726276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85117726276&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85117726276

SN - 1543-0790

VL - 19

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

IS - 8

ER -

Cases in the management of metastatic colorectal cancer: Regorafenib as second-line therapy after FOLFOXIRI plus bevacizumab in a patient with a KRAS mutation

ASJC Scopus subject areas

Other files and links

Cite this